Booster Phase News Today

arabia, john roberts in washington. >> sandra: happy friday to you. see what gets done as the president continues his trip abroad. im sandra smith here in new york. the president greeting the saudi crown prince with the fist bump that has now been seen around the world amid speculation whether the two leaders would shake hands. part of the high stakes meeting focusing on talks to boost energy output there, as gas prices soar in the united states. but the white house is tamping down any...

Genetic code and the observations from south africa. thats why the w.h.o. has called it concerning because it combines the genetic code that reduces vaccine effectiveness and treatment effectiveness, but also greater transmissibility. >> when you hear that some of these pharmaceutical companies are saying we may have to amend our vaccine somewhat to account for omicron. there are a lot of people who got their vaccine but thaw now in the booster phase. should they wait to get the boosters? >> abs...

Risk. retail workers at high risk. police, more police have died by covid than gun violence. this is important to protect the workers. this is important to protect sew side. businesses want to open and the fastest way to open for them is to get control of the virus and the best method to intervene is the vaccine. so you cant be -- we want to open, we want to get back to normal business but were not going to be for a mandate to get people vaccinated. those are inconsistent policies and we urge bu...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate VALNEVAJuly 19, 2021 GMT Saint-Herblain (France) and New York, NY, July 19, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc. ...

Pfizer Forward-Looking Statements The information contained in this release is as of March 8, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.  This release contains forward-looking information about a Lyme disease vaccine candidate, VLA15, and a collaboration between Pfizer and Valneva for VLA15, including their potential benefits and a potential phase 3 start, that involves su...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate VALNEVAMarch 8, 2021 GMT The Phase 2 study will include both adult and pediatric subjects with an aim to support acceleration of the vaccine candidate’s pediatric program   VLA15 will be  tested at two different schedules (Month 0-2-6 or Month 0-6) receiving the selected dose of 180µg VLA15 is the only Lyme...

Valneva and Pfizer have initiated a Phase 2 study for their Lyme disease vaccine candidate: which is the only active Lyme disease vaccine in clinical development today.